What is the 13F Pro Quality Score for SCYX?

13F Pro ranks SCYNEXIS INC (SCYX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SCYX's current score at https://13fpro.ai/company/SCYX (free sign-up required for the full ranking).

Where does 13F Pro source SCYX data?

All SCYNEXIS INC fundamentals and ownership data come directly from SEC EDGAR. SCYNEXIS INC files with the SEC under CIK 1178253. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SCYX in?

SCYNEXIS INC (SCYX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SCYX research updated on 13F Pro?

SCYX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SCYNEXIS INC(SCYX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1178253 SCYX stock profile & AI dashboard →

13F Pro Quality Score

14.2/100

Rank #2,868 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SCYX Scores 14/100

exact factor attribution · 2026-09-11

SCYX's composite is driven by earnings growth, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+1.8 pts

85th pct

Shareholder dilution

-1.6 pts

17th pct

Institutional flow

-2.3 pts

3th pct

Capital efficiency

-3.0 pts

20th pct

Earnings quality

-4.4 pts

6th pct

Profitability

-4.9 pts

18th pct

Free cash flow

-5.5 pts

14th pct

Scale

-5.9 pts

10th pct

Revenue growth

-9.9 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SCYX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for SCYNEXIS INC (SCYX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SCYX at 14.2/100 on a 32-signal composite quality model, placing it at rank #2,868 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), SCYNEXIS INC reports quarterly revenue of $235.0K, net income of $7.4M. Top institutional holders of SCYX by reported 13-F value include GREAT POINT PARTNERS, Squadron Capital Management, Propel Bio Management, based on the most recent SEC filings. SCYX trades on the Nasdaq exchange and files with the SEC under CIK 1178253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SCYNEXIS INC directly from SEC EDGAR. SCYNEXIS INC's 13F Pro composite quality score has ranged between 9 and 75 since 2021, currently 14.2 — a declining long-term trajectory across 17 quarterly and live scoring snapshots.

✦

Fun facts about SCYNEXIS INC

Quirks, history, and lore behind SCYX — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company listed on Nasdaq, focused entirely on treating serious fungal infections in humans.
2
The Numbers
Annual revenue in the low tens of millions — classic commercial-stage biotech territory, burning cash while trying to grow a single approved drug.
3
The History
Founded in the early 2000s, the company spent years in drug discovery before pivoting hard into antifungal therapeutics, a niche most big pharma ignores.
4
The Secret
Its lead compound targets drug-resistant Candida infections — the same family of pathogens that inspired the name of HBO's zombie apocalypse show, which is… great for awareness.
5
The Lore
It achieved a rare feat for a tiny biotech: winning FDA approval for a first-in-class oral antifungal — the first new class of antifungal approved in over two decades.
6
The Giveaway
Its FDA-approved drug ibrexafungerp, sold as Brexafemme, treats vaginal yeast infections with a novel mechanism — and the company's name itself riffs on "synexis", a fusion of science and connection.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$235.0K

Net Income

Q2 2026

$7.4M

ROIC

Q2 2026

-46.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+449.9% YoY

$20.6MFY 2025

FY22 $5.1MFY23 $140.1MFY24 $3.7MFY25 $20.6M

Net Income

+59.6% YoY

$-8.6MFY 2025

FY22 $-62.8MFY23 $67.0MFY24 $-21.3MFY25 $-8.6M

Operating Income

+56.7% YoY

$-16.1MFY 2025

FY22 $-85.8MFY23 $72.7MFY24 $-37.1MFY25 $-16.1M

EPS (Diluted)

+61.4% YoY

$-0.17FY 2025

FY22 $-1.47FY23 $1.39FY24 $-0.44FY25 $-0.17

Total Assets

-34.9% YoY

$59.0MFY 2025

FY22 $87.8MFY23 $128.4MFY24 $90.6MFY25 $59.0M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+78.0% YoY

$-5.3MFY 2025

FY22 $-79.9MFY23 $60.2MFY24 $-24.0MFY25 $-5.3M

Free Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$20.6M +449.9%	$3.7M -97.3%	$140.1M +2652.7%	$5.1M -61.3%	$13.2M	$0.00
Net Income	$-8.6M +59.6%	$-21.3M -131.8%	$67.0M +206.7%	$-62.8M -91.1%	$-32.9M +40.4%	$-55.2M
Operating Income	$-16.1M +56.7%	$-37.1M -151.1%	$72.7M +184.7%	$-85.8M -41.0%	$-60.8M -18.9%	$-51.1M
EPS (Diluted)	$-0.17 +61.4%	$-0.44 -131.7%	$1.39 +194.6%	$-1.47 -17.6%	$-1.25	—
Total Assets	$59.0M -34.9%	$90.6M -29.4%	$128.4M +46.2%	$87.8M -26.7%	$119.8M +16.9%	$102.5M
Total Debt	—	—	—	—	$34.4M	—
Operating Cash Flow	$-5.3M +78.0%	$-24.0M -139.9%	$60.2M +175.3%	$-79.9M -46.4%	$-54.6M -10.5%	$-49.4M
Free Cash Flow	—	—	—	—	$-54.6M -10.5%	$-49.4M

Get alerted when SCYX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SCYNEXIS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SCYX

GREAT POINT PARTNERS LLC
$3.8M944,292 sh
Squadron Capital Management LLC
$3.1M756,884 sh
Propel Bio Management, LLC
$2.2M543,478 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$2.2M543,478 sh
Woodline Partners LP
$1.6M387,520 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2M296,747 sh
Avidity Partners Management LP
$1.1M260,206 sh
KINGDON CAPITAL MANAGEMENT, L.L.C.
$1.0M247,811 sh
MILLENNIUM MANAGEMENT LLC
$735.8K180,788 sh
HEIGHTS CAPITAL MANAGEMENT, INC
$612.7K150,551 sh

Fund	Value	Shares
GREAT POINT PARTNERS LLC	$3.8M	944,292
Squadron Capital Management LLC	$3.1M	756,884
Propel Bio Management, LLC	$2.2M	543,478
ADAGE CAPITAL PARTNERS GP, L.L.C.	$2.2M	543,478
Woodline Partners LP	$1.6M	387,520
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	296,747
Avidity Partners Management LP	$1.1M	260,206
KINGDON CAPITAL MANAGEMENT, L.L.C.	$1.0M	247,811
MILLENNIUM MANAGEMENT LLC	$735.8K	180,788
HEIGHTS CAPITAL MANAGEMENT, INC	$612.7K	150,551

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SCYX on your watchlist

Track score changes the day SCYNEXIS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SCYX a good stock to buy?

13F Pro's AI-powered analysis of SCYNEXIS INC (SCYX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SCYX are available on the SCYX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SCYX is classified as a small company.

Which hedge funds own SCYX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SCYX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SCYNEXIS INC's investment landscape.